InsidersTradesSigma
Follow the Regeneron Pharmaceuticals, INC. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Regeneron Pharmaceuticals, INC. has published 425 insider filings. Market capitalisation: €81.8bn. The latest transaction was reported on 3 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: RYAN ARTHUR F. All data is free.
425
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€251m
109 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Regeneron Pharmaceuticals, INC. Buy (bullish), based on 27 analysts. Average price target: US$840.43.
32Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,965 of 29,063 companies
70.9
score / 100
Value57
Quality85
FCF yld4.6%
Earn yld5.5%
EV/EBITDA14.5x
ROE14%
Gross mgn85%
Net mgn31%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations425 total
1,131 shares@ US$857.000.0012% mcap3.7% of flowCommonSEC144:0001969223-26-000991
12,282 shares@ US$381.920.0056% mcap6.4% of flowCommon StockSEC:0001238303-26-000002:0
9,019 shares@ US$830.150.0089% mcap10.3% of flowCommon StockSEC:0001238303-26-000002:1
6,283 shares@ US$381.920.0028% mcap5.9% of flowCommon StockSEC:0001697422-26-000002:0
4,599 shares@ US$813.470.0044% mcap9.3% of flowCommon StockSEC:0001697422-26-000002:1
400 shares@ US$800.000.0004% mcap34.5% of flowCommon StockSEC:0001992352-26-000005:1
800 shares@ US$800.000.0008% mcap16.4% of flowCommon StockSEC:0001681643-26-000006:1
400 shares@ US$719.370.0004% mcap31.0% of flowCommon StockSEC:0001992352-26-000005:0
800 shares@ US$376.690.0004% mcap7.7% of flowCommon StockSEC:0001681643-26-000006:0
800 shares@ US$800.000.0008% mcap21.6% of flowCommonSEC144:0001969223-26-000871
400 shares@ US$800.000.0004% mcap100.0% of flowCommonSEC144:0001969223-26-000870
200 shares@ US$650.150.0002% mcap49.2% of flowCommon StockSEC:0001187443-26-000010:0
400 shares@ US$624.720.0004% mcap100.0% of flowCommon StockSEC144:0001968582-26-000693
1 shares@ US$771.320.2% of flowCommon StockSEC:0001104659-26-039613:0
3 shares@ US$772.760.7% of flowCommon StockSEC:0001104659-26-039613:1
8 shares@ US$773.591.8% of flowCommon StockSEC:0001104659-26-039613:2
8 shares@ US$774.581.8% of flowCommon StockSEC:0001104659-26-039613:3
14 shares@ US$775.583.1% of flowCommon StockSEC:0001104659-26-039613:4
13 shares@ US$776.622.9% of flowCommon StockSEC:0001104659-26-039613:5
9 shares@ US$777.422.0% of flowCommon StockSEC:0001104659-26-039613:6
4 shares@ US$778.240.9% of flowCommon StockSEC:0001104659-26-039613:7
40 shares@ US$779.719.0% of flowCommon StockSEC:0001104659-26-039613:8
7 shares@ US$777.461.6% of flowCommon StockSEC:0001187443-26-000006:0
1,638 shares@ US$376.6926.1% of flowCommon StockSEC:0001681643-26-000004:0
1,000 shares@ US$492.0040.3% of flowCommon StockSEC:0002009236-26-000001:0
25 of 425 declarations
关于 Regeneron Pharmaceuticals, INC.
Regeneron Pharmaceuticals, Inc. 是一家美国生物制药公司，在纳斯达克上市，股票代码为 REGN。该公司总部位于美国纽约州塔里敦，成立于 1988 年，已成为最具科学驱动力的大型生物技术公司之一。其业务模式高度整合，涵盖发现、开发和商业化，拥有强大的内部研究文化和专有平台，如 VelociSuite® 和 Regeneron Genetics Center®。（[regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai)） Regeneron 在多个治疗领域开发和商业化药物，包括眼科疾病、过敏和炎症性疾病、肿瘤学、心血管和代谢疾病、罕见病、传染病以及选定的神经系统疾病。其最知名的产品包括 Dupixent®（与赛诺菲共同销售）、用于视网膜疾病的 EYLEA® 和 EYLEA HD®、肿瘤领域的 Libtayo®，以及 Praluent®、Kevzara®、Evkeeza®、Inmazeb® 和 Veopoz® 等其他产品。尽管产品组合广泛，但该公司的盈利状况仍主要依赖于少数几个主要特许经营权，尤其是 Dupixent 和 EYLEA/EYLEA HD 眼科特许经营权，它们是其增长和盈利能力的核心。（[regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai)） 从竞争角度来看，Regeneron 被广泛认为是领先的生物技术公司，因为它能够将科学发现大规模转化为获批药物。该公司在抗体工程、蛋白质生物学和基因医学方面的专业知识使其能够保持深厚的研发管线，其中许多项目源于内部。在 2025 年和 2026 年初，Regeneron 继续扩大其商业产品组合和临床管线，在免疫学、眼科、肿瘤学和罕见病领域取得了监管批准和后期进展。（[regeneron.com](https://www.regeneron.com/about/our-company?utm_source=openai)） 近期亮点包括 FDA 于 2026 年 4 月批准 EYLEA HD，在某些视网膜适应症中给药间隔长达 20 周；2025-2026 年 Dupixent 获得多项新批准；以及 Regeneron 的首个基因药物和首个用于罕见听力损失适应症的基因疗法 Otarmeni™ 获得加速批准。该公司还宣布与 Telix 合作开发放射性药物，并与美国政府就某些药物的定价达成协议，同时重申其对国内研发和制造进行大量投资的承诺。对于国际投资者而言，Regeneron 仍然是健康与制药领域的高质量增长股，它结合了专有科学平台、深厚的研发管线以及在美国纳斯达克市场的领先商业特许经营权。（[investor.regeneron.com](https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-approved-fda-first-and-only-injectable/?utm_source=openai)）
